FDA warns Discover Health over unapproved CBD, CBG, HHC, and Delta-8 THC drugs, unsafe CBD/Delta-8 foods, and unapproved animal drugs.
What happened
FDA reviewed the company’s websites at discovercbd.com and activecbdoil.com and its Instagram from June to August 2023. FDA found products containing CBD, CBG, HHC, and Delta-8 THC marketed with claims to treat diseases such as cancer, epilepsy, PTSD, and opioid addiction, plus CBD/Delta-8 THC in foods and CBD in pet products.
What FDA found
The company markets CBD, CBG, HHC, and Delta-8 THC products with claims to treat cancer, epilepsy, PTSD, diabetes, glaucoma, and opioid addiction, making them unapproved new drugs.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The drug products’ labeling lacks adequate directions for use, so they are misbranded (labeling violates the law).
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5CBD added to coffee, gummies, and water is an unsafe food additive, making those foods adulterated (unsafe under the law).
FD&C Act sections 402(a)(2)(C)(i) and 409, 21 U.S.C. 342(a)(2)(C)(i) and 348(a)Delta-8 THC added to plant-based gummies is an unsafe food additive, making the gummies adulterated.
FD&C Act sections 402(a)(2)(C)(i) and 409, 21 U.S.C. 342(a)(2)(C)(i) and 348(a)CBD pet treats and tinctures are unapproved new animal drugs and are adulterated.
FD&C Act sections 512(a) and 501(a)(5), 21 U.S.C. 360b(a) and 351(a)(5)The CBD pet products also contain an unsafe food additive and are prohibited from interstate commerce.
FD&C Act sections 402(a)(2)(C)(i) and 301(ll), 21 U.S.C. 342(a)(2)(C)(i) and 331(ll)
What FDA wants
FDA advises the company that the products may not be introduced into interstate commerce as sold and points it to FDA’s cannabis-product information; no response deadline is stated in the provided letter.
Who should pay attention
- CBD and hemp brands selling foods, drugs, or pet products
- retailers and distributors of Delta-8 THC products
- companies making disease-treatment claims for CBD
This is a summary. Read the original letter on fda.gov.